Stephen Oh, MD, PhD


Clinical Pearls for the Management of Myelofibrosis

June 23rd 2022

Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.

Myelofibrosis: Novel Combination Strategies

June 16th 2022

Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.

Novel Agents in the Pipeline for Myelofibrosis

June 16th 2022

A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.

Myelofibrosis: Patient Monitoring and Triggers to Change Therapy

June 9th 2022

Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.

Selection and Management of JAK Inhibitor Therapy in MF

June 9th 2022

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

Myelofibrosis: Use of Fedratinib and Pacritinib Therapy

June 2nd 2022

Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.

Use of Ruxolitinib in Myelofibrosis

June 2nd 2022

Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.

Historical Approaches to the Management of MF

May 26th 2022

A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.

Factors in Selecting Therapy for Myelofibrosis

May 26th 2022

Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.

Myelofibrosis: Observation and Triggers to Initiate Therapy

May 19th 2022

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Risk Assessment and Staging of Myelofibrosis

May 19th 2022

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Addressing the Challenges in Diagnosing MF

May 12th 2022

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Making a Differential Diagnosis of Myelofibrosis

May 12th 2022

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.

Polycythemia Vera: Ruxolitinib Use and Goals of Therapy

May 5th 2022

A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.

Treatment Armamentarium for Polycythemia Vera

May 5th 2022

Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.

Making a Differential Diagnosis of Polycythemia Vera

April 28th 2022

Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.

A Brief Overview of Myeloproliferative Neoplasms

April 28th 2022

Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.

Dr. Oh on the Evolving Treatment Landscape in CLL

February 24th 2022

Stephen Oh, MD, PhD, discuses the evolving treatment landscape of chronic lymphocytic leukemia.

Dr. Oh Discusses the Differences Between Investigational JAK Inhibitors and Ruxolitinib in MPNs

January 26th 2019

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the differences between investigational JAK inhibitors and ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).

Dr. Oh on the Development of JAK Inhibitors in Myelofibrosis

October 20th 2018

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine, Siteman Cancer Center, discusses the development of JAK inhibitors in myelofibrosis.